Evaluating the Adverse Cognitive Effects of Medications

评估药物对认知的不良影响

• 批准号: 9038206
• 负责人: Noll L. Campbell
• 金额: $ 14.24万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9038206
• 关键词: Address; Affect; Alzheimer' s Disease; Anti-Cholinergics; Appointment; Biometry; Caring; Chronic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Cognition; Cognition Disorders; Cognitive; Cohort Studies; Comorbidity; Conflict (Psychology); Data; Data Set; Databases; Dementia; Development; Development Plans; Disease; Doctor of Pharmacy; Elderly; Enrollment; Epidemiology; Exercise; Exposure to; Extramural Activities; Foundations; Funding; Future; Genetic Predisposition to Disease; Goals; Health; Health Services Research; Health system; Healthcare Systems; Impaired cognition; Impairment; Indiana; Information Technology; Intervention; Investigation; K-Series Research Career Programs; Lipids; Literature; Measurement; Measures; Medical; Medical Records; Mentors; Monitor; Neuropsychological Tests; Neuropsychology; Observational Study; Outcome; Participant; Patient Self-Report; Pharmaceutical Preparations; Pharmacoepidemiology; Pharmacotherapy; Pharmacy facility; Population; Primary Health Care; Product Labeling; Prospective Studies; Publishing; Research; Research Activity; Research Design; Research Personnel; Research Project Grants; Residencies; Resources; Risk; Risk Factors; Staging; Test Result; Testing; Time; Training; United States Food and Drug Administration; Universities; Work; aged; aging brain; brain health; career; career development; cognitive function; cognitive performance; cohort; college; design; experience; high risk; human old age (65+); improved; interest; medical specialties; modifiable risk; neuropsychological; prospective; protective effect; racial diversity; safety net; skills

DESCRIPTION (provided by applicant): The Applicant: Noll Campbell, PharmD, FASCP, BCPP began his career by pursuing specialty training in geriatric pharmacotherapy through two residencies and has over 10 years of clinical experience. His interests in clinical research influenced him to establish a relationship with the geriatric clinical researchers at Indiana University. This relationship resulted in several activities and experiences that have provided the foundation for Dr. Campbell's future career in geriatric clinical research. In an effort to protect time for research activity and pursue his career goals, he transitioned to a research appointment with the Purdue University College of Pharmacy. With the support of this career development award he will develop skills in clinical trial design, pharmacoepidemiology, and biostatistics through didactic and experiential training exercises. Upon completion of the mentored career development award, Dr. Campbell will compete for extramural funding with future projects minimizing the adverse cognitive effects of medications among older adults. The Research Career Development Plan: This application proposes course work, a research strategy, and mentored activities provided by a panel of mentors. The mentoring team includes an expert in aging brain health services research (Dr. Malaz Boustani); a leader in pharmacoepidemiology (Dr. Mick Murray); an expert in biostatistics and epidemiology (Dr. Sujuan Gao); and an expert in neuropsychology (Dr. Fred Unverzagt). The career development plan intends to achieve the candidate's long-term career goals of: (1) developing skills in clinical trial design, pharmacoepidemiology, and biostatistics to support a research career improving the health of the aging brain; and (2) obtaining information technology skills necessary to use this valuable resource in future research. The Research Project: Previous literature describing the impact of medications on cognitive impairment has been limited by inaccurate measurements of medication exposure and cognitive impairment. This project proposes to address these limitations by using continuous and accurate measures of medication exposure and neuropsychological assessments. The population included in this analysis consists of older adults with cognitive impairment who are at high risk of developing dementia due to a significant burden of modifiable and non-modifiable risk factors. This population was enrolled in an observational study aimed at identifying risk factors for dementia. The study cohort receives care within a large healthcare system that captures all activity in a large medical record database, including medication dispensing data. Similarly, neuropsychological assessments conducted annually during the four-year prospective period will be used as a comprehensive measure of cognitive function. These results will provide preliminary evidence for future interventions aimed at reducing the adverse cognitive effects of medications and ultimately improving the health of the aging brain.

描述（由申请人提供）： 申请人：Noll Campbell，药学博士、FASCP、BCPP 通过两次住院医师接受老年药物治疗专业培训开始了他的职业生涯，并拥有 10 多年的临床经验。他对临床研究的兴趣促使他与印第安纳大学的老年临床研究人员建立了联系。这种关系带来了多项活动和经验，为 为坎贝尔博士未来从事老年临床研究的职业生涯奠定了基础。为了努力保护 由于没有时间进行研究活动并追求自己的职业目标，他转到普渡大学药学院担任研究职务。在该职业发展奖的支持下，他将通过教学和体验式培训练习来培养临床试验设计、药物流行病学和生物统计学方面的技能。完成指导职业发展奖后，坎贝尔博士将与未来的项目竞争外部资金，以尽量减少药物对老年人的不良认知影响。研究职业发展计划：该申请提出了课程作业、研究策略以及由导师小组提供的指导活动。指导团队包括老龄化大脑健康服务研究专家（Malaz Boustani 博士）；药物流行病学领域的领军人物（Mick Murray 博士）；生物统计学和流行病学专家（高素娟博士）；以及神经心理学专家（Fred Unverzagt 博士）。职业发展计划旨在实现候选人的长期职业目标：（1）发展临床试验设计、药物流行病学和生物统计学方面的技能，以支持改善衰老大脑健康的研究生涯； (2) 获得在未来研究中使用这一宝贵资源所需的信息技术技能。研究项目：先前描述药物对认知障碍影响的文献因药物暴露和认知障碍的测量不准确而受到限制。该项目建议通过使用连续且准确的药物暴露测量和神经心理学评估来解决这些局限性。本分析中包含的人群包括患有认知障碍的老年人，由于可改变和不可改变的危险因素的巨大负担，他们处于患痴呆症的高风险中。该人群参加了一项旨在确定痴呆症危险因素的观察性研究。研究队列在大型医疗保健系统中接受护理，该系统捕获大型医疗记录数据库中的所有活动，包括药物配药数据。同样，在四年的前瞻性期间每年进行的神经心理学评估将被用作认知功能的综合衡量标准。这些结果将为未来旨在减少药物对认知的不良影响并最终改善衰老大脑健康的干预措施提供初步证据。